The Corticobasal Degeneration Functional Rating Scale (CBD-FS)
Objective: To develop a patient/care giver-reported scale that is capable of assessing functional disability in CBD that can be easily and reliably used in clinical…A Comparison of Muscular Atrophy Between Botulinum Toxin Types A and B
Objective: To compare and quantify the degree of muscular atrophy (MA) in botulinum toxin (BT) type A (Botox) and type B (Myobloc). A secondary endpoint…The Adult Spasticity International Registry (ASPIRE) Study: 1 Year Results
Objective: To evaluate the 1-year interim onabotulinumtoxinA safety, effectiveness, and exploratory treatment utilization data from the ASPIRE study. Background: OnabotulinumtoxinA treatment for patients with spasticity…The Adult Spasticity International Registry (ASPIRE) Study: Treatment Utilization Patterns in Patients Treated for Both Upper and Lower Limb Spasticity
Objective: To examine the treatment patterns of onabotulinumtoxinA utilization in patients treated for upper and lower limb spasticity, in combination, from the ASPIRE study (1…Efficacy of IncobotulinumtoxinA in Treatment of Lower Limb Spasticity in Adults
Objective: To evaluate the effectiveness of incobotulinumtoxinA for treating key clinical patterns of lower limb (LL) spasticity (eg, pes equinovarus) using a post-hoc analysis. Background:…Efficacy of IncobotulinumtoxinA for the Treatment Of Shoulder Spasticity
Objective: To evaluate efficacy of botulinum toxin for shoulder spasticity using a post-hoc analysis. Background: Botulinum toxin has been shown to be effective for treating…CAPN1 mutations are associated with a syndrome of combined spasticity and ataxia
Objective: To report a new family with combined spasticity and ataxia harboring mutations in the CAPN1 gene. Background: Hereditary spastic paraplegias (HSPs) are a heterogeneous group…Effect of early AbobotulinumtoxinA (Dysport®) use after stroke on the time to reach reinjection criteria: asymptomatic versus symptomatic patients
Objective: To determine if early post-stroke (within 12 weeks) abobotulinumtoxinA (aboBoNT-A;Dysport®) injections delay appearance or progression of upper limb symptomatic spasticity. Background: Muscle tone changes…Time to retreatment with botulinum toxin A in upper limb spasticity management: initial data from the Upper Limb International Spasticity (ULIS)-III study
Objective: The ongoing ULIS-III study aims to describe real-life clinical practice and assess patient‑centered goal attainment with integrated upper limb spasticity (ULS) management that includes…Genotype-Phenotype correlations and expansion of the molecular spectrum of AP4M1-related Hereditary Spastic Paraplegia
Objective: To identify possible novel variants in a HSP family from Greece. Background: Autosomal recessive hereditary spastic paraplegia (HSP) due to AP4M1 mutations is a…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.